Diablo Clinical Research

Executive Summary

Diablo Clinical Research is a private, single-site clinical research organization (CRO) based in Walnut Creek, California, founded in 1995. The company specializes in conducting Phase 1–3 clinical trials across multiple therapeutic areas, with a historical core expertise in diabetes. Operating both outpatient and inpatient units on-site, it provides services to pharmaceutical and device sponsors to generate valuable study data. As an independent CRO, Diablo Clinical Research plays a critical role in the drug development ecosystem, offering flexibility and personalized service compared to large global CROs. The company's long-standing presence and focus on diabetes position it well to benefit from the growing demand for clinical trial services, particularly in metabolic diseases. However, as a private company with no disclosed funding or valuation, its financial performance and growth trajectory remain opaque, limiting visibility. Overall, Diablo Clinical Research represents a stable but niche player in the CRO space, with potential for steady contract wins.

Upcoming Catalysts (preview)

• Q3 2026New contract win with a top-20 pharmaceutical company for a diabetes trial60% success
• Q4 2026Expansion of site capacity or addition of new therapeutic area capabilities40% success
• Q1 2027Initiation of a Phase 2 trial in a non-diabetes metabolic indication30% success